The brochures, whitepapers, publications, posters and videos, in this section will enable you to learn more about our Solupore system. Please do not hesitate to contact us to discuss your requirements further.
This is the first study to successfully demonstrate the reprogramming of blood cell types using srRNA to produce functional iPSCs.
A scalable, rapid & automated manufacturing platform, Solupore®, a flexible offering for both autologous and allogeneic cell therapies
Solupore® transfected cells isolated using Sony’s CGX10 yield highly cytotoxic CAR-T cells.
Increased functional potency of multi-edited CAR-T cells manufactured by a non-viral transfection system.
Enhanced Stem Cell Memory and Cytotoxic Function in Engineered T Cells Expanded for 7 days to >1.3×109
Solupore® Triple Knock-Out Transfected T cell Expansion Equivalent to Untransfected in G-Rex Platform
Solupore® Triple Knock-Out Transfected T cell Expansion Equivalent to Untransfected in G-Rex® Platform.
Find out more about a novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.
Find out more about our Vector-free intracellular delivery by reversible permeabilization.
Find out how Solupore® by Avectas offers an automated, reproducible transfection system for the delivery of a wide variety of cargo (RNA, DNA, protein) to primary immune cells used in clinical cell therapy applications.
Download our PDF and see how Solupore is accelerating the future of cell therapies through healthier and more functional cells for patients.
Solupore® demonstrates superior cellular avidity which is essential for optimising cell therapy processes.
Solupore® knock-in using GenScript GenExact™ single-stranded DNA
Activation-Free Transfection with Solupore®: Preserving Naïve T cell Phenotypes